FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • April 12th, 2022 • NANOMIX Corp • Pharmaceutical preparations
This First Amendment to the Development and License Agreement (the “First Amendment”) is entered into this 1st of September 2018 (the “Effective Date”).
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • April 12th, 2022 • NANOMIX Corp • Pharmaceutical preparations • California
This Development and License Agreement (“Agreement”) is entered into as of this 26th day of September, 2017 (the “Effective Date”) by and between RedPharm (Beijing) Biotechnology Co., Ltd. (“RedPharm”), having its principal place of business at Room 1806, Block A, Tower Two, Wangjing SOHO, Chaoyang District, Beijing, China; Medical Technology Associates II, Inc. (“MTA2”; collectively with RedPharm, “Licensees” and each a “Licensee”), having its principal place of business at 8 Cedar Point Road, Durham, New Hampshire 03824; and Nanomix, Inc. (“NANOMIX”), having its principal place of business at 1440 Stanford Avenue, Emeryville, California 94608.
